BMO Capital Upgrades Incyte Corporation to Hold, Sets $94 Target
BMO Capital raises Incyte Corporation's rating to hold with a $94 price target, a 13.33% downside from the current price.
Key Points
- BMO Capital upgraded Incyte Corporation to a hold rating with a $94 price target on June 22, 2026.
- BMO Capital's $94 price target implies 13.33% downside from Incyte Corporation's ($INCY) current $108.46 share price.
- Shares of Incyte Corporation traded near $98.22 on Monday, with a market cap of $19.6 billion and a P/E ratio of 13.89.
- Insiders recently bought shares, and analysts have varied ratings with a consensus target of $109.35.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BMO Capital has upgraded Incyte Corporation (NasdaqGS: INCY) to a hold rating, setting a price target of $94. Analyst Evan Seigerman announced the change on June 22, 2026. This adjustment comes as the stock traded near $98.22 on Monday.
BMO Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Incyte Corporation Stock Down 12.8%
Shares of Incyte Corporation traded around $98.22 on Monday. The company, valued at approximately $19.6 billion, has a P/E ratio of 13.89 and a forward P/E of 10.72. With a beta of 0.79, Incyte's stock has experienced a 52-week low of $66.74 and a high of $112.29. The stock's 50-day moving average is $98.17, while its 200-day moving average is $96.80. Incyte maintains a strong liquidity position with a current ratio of 3.68 and a quick ratio of 3.40, alongside a debt-to-equity ratio of 0.70.
$INCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Incyte reported revenue of approximately $5.36 billion, reflecting a growth of 20.9%. The company's net margin stands at 26.7%, with a return on equity of 30.8%. Earnings per share (EPS) is reported at $7.07. Incyte's next earnings date is scheduled for July 28, 2026.
Insider Buying and Selling at Incyte Corporation
Several insiders at Incyte Corporation recently bought shares on June 8, 2026. Otis Brawley, Edmund Harrigan, Paul Clancy, Katherine High, and Jacqualyn Fouse each purchased shares, with Brawley and High acquiring 6,111 shares each. These transactions were not part of a planned trading program.
Analysts Set New Price Targets
On June 22, 2026, BMO Capital upgraded Incyte to a hold rating with a $94 price target. HC Wainwright & Co. maintained its buy rating with a $140 target on June 9, 2026, while Bernstein initiated coverage with a hold rating and a $99 target on May 22, 2026. Overall, 23 analysts have a consensus recommendation of 'buy' with a mean target price of $109.35.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company based in Wilmington, Delaware. It focuses on discovering, developing, and commercializing therapeutics, primarily in oncology, across the United States, Europe, Canada, and Japan. The company is known for its products like Jakafi and Iclusig, used in treating various cancers and other severe conditions. Incyte collaborates with major firms like Novartis and Lilly and has a strong research and development pipeline. It was incorporated in 1991 and employs about 2,844 people under the leadership of CEO William J. Meury.
Bottom Line
Incyte Corporation's stock has seen varied analyst opinions, with BMO Capital recently upgrading it to a hold rating. The company's strong financial position and active insider buying may be of interest to investors. However, it's important to remember that analyst ratings and insider activities are just part of the broader investment landscape.
Get Incyte Corporation alerts
New 13F filings, insider trades, and analyst moves on $INCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.